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Introduction {#embj201592559-sec-0001}
============

Mutations in several aggregation‐prone RNA‐binding proteins (RBPs) are increasingly linked to various neurodegenerative diseases. Such mutations constitute a major cause of amyotrophic lateral sclerosis (ALS), the most frequent adult‐onset motor neuron disease, with mutations in TDP‐43 (Gitcho *et al*, [2008](#embj201592559-bib-0026){ref-type="ref"}; Kabashi *et al*, [2008](#embj201592559-bib-0040){ref-type="ref"}; Sreedharan *et al*, [2008](#embj201592559-bib-0080){ref-type="ref"}) and FUS (Kwiatkowski *et al*, [2009](#embj201592559-bib-0047){ref-type="ref"}; Vance *et al*, [2009](#embj201592559-bib-0090){ref-type="ref"}) accounting each for about 5% of familial ALS cases. Even in the absence of mutations, abnormal cytoplasmic inclusions of TDP‐43 represent a pathological hallmark of sporadic ALS, non‐SOD1 familial ALS, and frontotemporal dementia (FTD) (Neumann *et al*, [2006](#embj201592559-bib-0062){ref-type="ref"}, [2009](#embj201592559-bib-0063){ref-type="ref"}), a neurodegenerative condition characterized by behavioral and language deficits. Similarly, compromised FUS nuclear localization and cytoplasmic FUS aggregates are found in ALS patients carrying *FUS* mutations, as well as in a subset of FTD patients without TDP‐43 pathology (Mackenzie *et al*, [2010](#embj201592559-bib-0055){ref-type="ref"}). Consistent with a central role of RNA processing misregulation in ALS and FTD pathogenesis, mutations in several other RBPs were recently identified, in particular TAF15 and EWSR1, two proteins from the same family as FUS (Couthouis *et al*, [2011](#embj201592559-bib-0013){ref-type="ref"}, [2012](#embj201592559-bib-0014){ref-type="ref"}), and other less closely related RBPs such as ataxin 2 (Elden *et al*, [2010](#embj201592559-bib-0020){ref-type="ref"}), hnRNPA2B1 (Kim *et al*, [2013](#embj201592559-bib-0043){ref-type="ref"}), hnRNPA1 (Kim *et al*, [2013](#embj201592559-bib-0043){ref-type="ref"}), and matrin‐3 (Johnson *et al*, [2014](#embj201592559-bib-0038){ref-type="ref"}).

Disease‐associated mutations in RBPs typically disrupt the normal nuclear localization of mutant proteins, with concomitant sequestration of the endogenous wild‐type protein into cytoplasmic aggregates (Kim *et al*, [2013](#embj201592559-bib-0043){ref-type="ref"}; Vance *et al*, [2013](#embj201592559-bib-0091){ref-type="ref"}). Mutations are either located in highly unstructured prion‐like protein domains, resulting in a higher propensity to aggregate (Kim *et al*, [2013](#embj201592559-bib-0043){ref-type="ref"}), or in the vicinity of the nuclear localization signal (NLS), impairing nuclear import of the protein. For instance, the NLS of FUS is an atypical PY‐NLS (Dormann *et al*, [2010](#embj201592559-bib-0019){ref-type="ref"}) located at the C‐terminus of the protein that represents a mutational hot spot in ALS patients. Along with missense mutations, several truncating or frameshift mutations deleting the FUS NLS have been identified in ALS patients (Fig [EV1](#embj201592559-fig-0001ev){ref-type="fig"}) and are often associated with juvenile onset and rapid disease progression (Baumer *et al*, [2010](#embj201592559-bib-0005){ref-type="ref"}; Waibel *et al*, [2010](#embj201592559-bib-0092){ref-type="ref"}, [2013](#embj201592559-bib-0093){ref-type="ref"}; Zou *et al*, [2013](#embj201592559-bib-0100){ref-type="ref"}; Calvo *et al*, [2014](#embj201592559-bib-0009){ref-type="ref"}; Deng *et al*, [2014](#embj201592559-bib-0016){ref-type="ref"}). In most instances, *FUS* mutations are dominantly inherited. However, it is noteworthy that a recessive inheritance pattern is occasionally observed in ALS patients (Kwiatkowski *et al*, [2009](#embj201592559-bib-0047){ref-type="ref"}; Bertolin *et al*, [2014](#embj201592559-bib-0007){ref-type="ref"}).

![Relevance of *Fus* ^*Δ*^ ^*NLS*^ mice to human ALS\
Upper panel: Scheme of the wild‐type FUS protein. The NLS, encoded by exon 15, includes the C‐terminal amino acids (aa 507--526, boundaries shown by the two dashed lines). Middle panels: 11 frameshift mutations (upper middle panel) and 2 truncating mutations (lower middle panel) in the *FUS* gene have been identified in ALS families. The corresponding mutant FUS proteins are shown. Insertions of abnormal polypeptide sequences induced by frameshift mutations are shown as red boxes. Lower panel: structure of FUS ^∆^ ^NLS^ protein in *Fus* ^*Δ*^ ^*NLS*^ mice.](EMBJ-35-1077-g003){#embj201592559-fig-0001ev}

FUS and TDP‐43 normally shuttle between the nucleus and cytoplasm, and defective nuclear import may lead to both loss of their nuclear functions and deregulation of their cytoplasmic roles. In the nucleus, FUS and TDP‐43 are involved in regulation of pre‐mRNA splicing, transcription, and microRNA biogenesis, all processes that may be affected by their depletion from the nucleus (Morlando *et al*, [2012](#embj201592559-bib-0060){ref-type="ref"}; Ling *et al*, [2013](#embj201592559-bib-0051){ref-type="ref"}). Consistently, reductions of TDP‐43 or FUS were associated with altered expression and splicing of several hundreds of genes (Polymenidou *et al*, [2011](#embj201592559-bib-0067){ref-type="ref"}; Tollervey *et al*, [2011](#embj201592559-bib-0085){ref-type="ref"}; Ishigaki *et al*, [2012](#embj201592559-bib-0037){ref-type="ref"}; Lagier‐Tourenne *et al*, [2012](#embj201592559-bib-0048){ref-type="ref"}; Rogelj *et al*, [2012](#embj201592559-bib-0069){ref-type="ref"}; Ling *et al*, [2015](#embj201592559-bib-0052){ref-type="ref"}), and both proteins are critically involved in the processing of long pre‐mRNAs (Polymenidou *et al*, [2011](#embj201592559-bib-0067){ref-type="ref"}; Lagier‐Tourenne *et al*, [2012](#embj201592559-bib-0048){ref-type="ref"}; Ling *et al*, [2013](#embj201592559-bib-0051){ref-type="ref"}; Sibley *et al*, [2015](#embj201592559-bib-0077){ref-type="ref"}). Cytosolic functions of FUS and TDP‐43 include transport (Alami *et al*, [2014](#embj201592559-bib-0001){ref-type="ref"}) and/or storage (Han *et al*, [2012](#embj201592559-bib-0028){ref-type="ref"}) of mRNA in the cytoplasm with a crucial role in the formation of stress granules (Li *et al*, [2013](#embj201592559-bib-0050){ref-type="ref"}).

Although several lines of evidence indicate that cytoplasmic mislocalization of RBPs is a key event in disease pathogenesis, definitive *in vivo* evidence is lacking and the relative contributions of loss and gain of function still need to be established. Indeed, it remains unknown whether loss of nuclear function of mutant RBPs is sufficient to trigger motor neuron disease or whether a cytosolic gain of function is also involved. There have been two major hurdles in answering these questions. First, ALS‐associated RBPs are crucial for cell physiology, and overexpression of wild‐type proteins causes widespread phenotypes (Huang *et al*, [2011](#embj201592559-bib-0033){ref-type="ref"}; Mitchell *et al*, [2013](#embj201592559-bib-0058){ref-type="ref"}; Sephton *et al*, [2014](#embj201592559-bib-0075){ref-type="ref"}). This represents a major drawback when attempting to discern the pathophysiological effects of disease‐causing mutations in overexpression models. Second, potent autoregulatory mechanisms control cellular levels of RBPs. For instance, both TDP‐43 (Ayala *et al*, [2011](#embj201592559-bib-0004){ref-type="ref"}; Polymenidou *et al*, [2011](#embj201592559-bib-0067){ref-type="ref"}; D\'Alton *et al*, [2015](#embj201592559-bib-0015){ref-type="ref"}) and FUS (Lagier‐Tourenne *et al*, [2012](#embj201592559-bib-0048){ref-type="ref"}; Zhou *et al*, [2013](#embj201592559-bib-0099){ref-type="ref"}; Dini Modigliani *et al*, [2014](#embj201592559-bib-0018){ref-type="ref"}) control their own levels by binding to their mRNAs. As a consequence, the levels of endogenous TDP‐43 or FUS proteins are strikingly reduced in animal models overexpressing wild‐type or mutant TDP‐43 and FUS (Wegorzewska *et al*, [2009](#embj201592559-bib-0095){ref-type="ref"}; Huang *et al*, [2011](#embj201592559-bib-0033){ref-type="ref"}; Arnold *et al*, [2013](#embj201592559-bib-0003){ref-type="ref"}; Mitchell *et al*, [2013](#embj201592559-bib-0058){ref-type="ref"}; Sephton *et al*, [2014](#embj201592559-bib-0075){ref-type="ref"}).

Here, we use homologous recombination techniques to circumvent issues inherent to overexpression animal models. We systematically compare the pathological and molecular features of two novel mouse models either expressing a truncated FUS protein that lacks the NLS and localizes within the cytoplasm (knockin mice) or harboring a genomic mutation associated with complete absence of FUS protein (knockout mice). Both mice expressing mutant cytoplasmic FUS and mice completely devoid of FUS died at birth of respiratory insufficiency. Using genomic approaches, we determined that FUS knockin mice display expression and splicing alterations consistent with loss of FUS nuclear function. However, mice expressing truncated cytoplasmic FUS, but not FUS knockout mice, exhibit perinatal motor neuron loss, which can be rescued by motor neuron‐restricted reversal of the mutant FUS gene to wild‐type FUS. These findings demonstrate that cytoplasmic FUS leads to loss of nuclear FUS function, yet exerts a toxic gain of function within the cytoplasm of motor neurons necessary to trigger neuronal death.

Results {#embj201592559-sec-0002}
=======

Cytoplasmic mislocalization of mutant FUS in *Fus* ^*ΔNLS/ΔNLS*^ mice {#embj201592559-sec-0003}
---------------------------------------------------------------------

With the aim to investigate *in vivo* consequences of altered FUS localization, we generated a mouse model with targeted deletion of the PY‐NLS, encoded by the last exon of the *Fus* gene (exon 15). This mutation closely mimics ALS‐causing truncating mutations of *FUS* (Fig [EV1](#embj201592559-fig-0001ev){ref-type="fig"}). We opted for a strategy that would not only result in ablation of exon 15, but also allow for CRE‐mediated reversal to the wild‐type locus. Due to the small size of intron 14, we engineered the *Fus* locus to include, in intron 12, a floxed cDNA encoding exons 13 and 14 of *Fus*, followed by 3 transcription stop cassettes and a poly‐adenylation signal (Fig [1](#embj201592559-fig-0001){ref-type="fig"}A). Germ line transmission of the recombinant allele was obtained (Fig [1](#embj201592559-fig-0001){ref-type="fig"}B) and mice heterozygous and homozygous for the targeted allele will hereafter be referred to as *Fus* ^*ΔNLS/+*^ and *Fus* ^*ΔNLS/ΔNLS*^, respectively. Homozygous *Fus* ^*ΔNLS/ΔNLS*^ mice died shortly after birth, and tissues dissected at birth (P0) were analyzed for expression and localization of FUS^∆NLS^ mRNA and protein. The ΔNLS mRNA could be detected by RT--PCR in tissues of *Fus* ^*ΔNLS/+*^ and *Fus* ^*ΔNLS/ΔNLS*^ mice (Figs [1](#embj201592559-fig-0001){ref-type="fig"}C and [EV2](#embj201592559-fig-0002ev){ref-type="fig"}A). FUS protein was detected by immunoblotting in *Fus* ^*ΔNLS/+*^ and *Fus* ^*ΔNLS/ΔNLS*^ brain, spinal cord, and muscle protein extracts using antibodies targeting the internal or N‐terminal parts of FUS (Figs [1](#embj201592559-fig-0001){ref-type="fig"}D and [EV2](#embj201592559-fig-0002ev){ref-type="fig"}B). Contrastingly, no signal was found in *Fus* ^*ΔNLS/ΔNLS*^ protein extracts when using two different antibodies that recognize the C‐terminal NLS of FUS (Figs [1](#embj201592559-fig-0001){ref-type="fig"}D and [EV2](#embj201592559-fig-0002ev){ref-type="fig"}B), demonstrating that the engineered *Fus* gene leads to the generation of a FUS protein devoid of NLS. FUS protein levels were hetero‐geneous in *Fus* ^*ΔNLS/+*^ brains (Fig [1](#embj201592559-fig-0001){ref-type="fig"}D). As expected, FUS protein localized to the nucleus in cultured mouse embryonic fibroblasts (MEFs) of *Fus* ^+/+^ mice. In striking contrast, FUS redistributed from the nuclear compartment to the cytoplasm in *Fus* ^*ΔNLS/ΔNLS*^ MEFs (Fig [EV2](#embj201592559-fig-0002ev){ref-type="fig"}C) and was detected in both the nucleus and the cytoplasm of *Fus* ^*ΔNLS/+*^ MEFs (Fig [EV2](#embj201592559-fig-0002ev){ref-type="fig"}C). Consistently, in *Fus* ^*ΔNLS/ΔNLS*^ newborn mice, immunostaining revealed that mutant FUS is localized to the cytoplasm of spinal motor neurons and cortical neurons, contrasting with the normal nuclear localization in *Fus* ^*+/+*^ neurons (Fig [1](#embj201592559-fig-0001){ref-type="fig"}E and F). In *Fus* ^*ΔNLS/+*^ mice, FUS is detected in both the nucleus and the cytoplasm of motor neurons (Fig [1](#embj201592559-fig-0001){ref-type="fig"}E). Thus, the *Fus* ^*ΔNLS*^ allele effectively leads to the expression of a truncated FUS protein that lacks the NLS and localizes predominantly to the cytoplasm.

![FUS mislocalization in *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^ mice\
Schematic representation of the *Fus* gene locus (upper panel). Lower panels depict exons 11--15 in the wild‐type allele (left) and ∆NLS allele (right) with localization of PCR primers used for genotyping (gDNA, used in B) and for RT--PCR (Total and ∆NLS, used in C). Arrow: translational start site. STOP cassettes are indicated in red; loxP sites as black triangles; coding regions are in dark blue and UTRs in light blue. Location of the region encoding the nuclear localization signal (NLS) is indicated in exon 15.Representative PCR genotyping results from 2 *Fus* ^+/+^, 2 *Fus* ^*Δ*^ ^*NLS*^ ^/+^, and 2 *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^ knockin mice using primers designed around the distal loxP site of the *Fus* ^*Δ*^ ^*NLS*^ allele and shown as gDNA in (A). The expected size of the PCR product of the ∆NLS allele is 240 bp; the size of wild‐type allele is 160 bp.RT--PCR analysis of brain from 2 *Fus* ^+/+^, 2 *Fus* ^*Δ*^ ^*NLS*^ ^/+^, and 2 *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^ knockin P0 mice using primers located in the STOP cassette, and thus specific to the ∆NLS mRNA (∆NLS, upper panel), or primers located in exon 11, that is, upstream of the floxed cDNA insertion, and thus amplifying total *Fus*‐derived mRNA (Total, middle panel). PCR amplification of 18S rRNA is shown as a standard gene (lower panel).Immunoblot analysis of FUS protein in cerebral cortex of 2 *Fus* ^+/+^, 2 *Fus* ^*Δ*^ ^*NLS*^ ^/+^, and 2 *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^ knockin mice using a combination of two different antibodies targeting either the C‐terminal (C‐ter. 1 and C‐ter. 2) NLS, the N‐terminal part (N‐ter. 1), or an internal part (N‐ter. 2) of FUS. Molecular weight markers are shown on the left, and apparent MW is indicated.Double immunostaining for the motor neuronal marker ChAT and Fus (N‐terminal part) in the ventral horn of spinal cord.Double immunostaining for nuclei (DAPI, blue) and Fus (N‐terminal part) in the cerebral cortex.\
Source data are available online for this figure.](EMBJ-35-1077-g002){#embj201592559-fig-0001}

![Expression of the *Fus* gene in various tissues of *Fus* ^*Δ*^ ^*NLS*^ mice\
RT--PCR analysis of spinal cord and gastrocnemius muscle from 2 *Fus* ^+/+^, 2 *Fus* ^*Δ*^ ^*NLS*^ ^/+^, and 2 *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^ P0 mice using primers located in the STOP cassette, and thus specific to the *Fus* ∆NLS mRNA (∆NLS, upper panel), or primers located in exon 11 and 12, that is, upstream of the floxed cDNA insertion, and thus amplifying total *Fus* mRNA (Total, lower panel).Immunoblot analysis of FUS protein in spinal cord and gastrocnemius of 2 *Fus* ^+/+^, 2 *Fus* ^*Δ*^ ^*NLS*^ ^/+^, and 2 *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^ mice using two different antibodies targeting the C‐terminal (C‐ter. 1 and C‐ter. 2) NLS or antibodies targeting the N‐terminal (N‐ter. 1) and internal parts (N‐ter. 2) of FUS.Representative confocal images for fluorescence immunocytochemical localization of FUS protein in mouse embryonic fibroblasts (MEFs).](EMBJ-35-1077-g005){#embj201592559-fig-0002ev}

Both cytoplasmic mislocalization of FUS and complete loss of FUS result in perinatal lethality {#embj201592559-sec-0004}
----------------------------------------------------------------------------------------------

*Fus* ^*ΔNLS/ΔNLS*^ mice were born alive, but died within minutes after birth, while *Fus* ^*ΔNLS/+*^ mice survived the perinatal period. The body length and weight of *Fus* ^*ΔNLS/ΔNLS*^ pups were slightly but significantly reduced as compared to *Fus* ^*+/+*^ and *Fus* ^*ΔNLS/+*^ newborn mice (Fig [2](#embj201592559-fig-0002){ref-type="fig"}A--C). The cause of death appeared to be respiratory insufficiency, as *Fus* ^*ΔNLS/ΔNLS*^ animals showed poor respiratory movements and cyanosis, and H&E staining of sections through the lung revealed uninflated lungs with complete alveolar atelectasis (Fig [2](#embj201592559-fig-0002){ref-type="fig"}D).

![Perinatal lethality in *Fus* ^*∆*^ ^*NLS*^ ^*/∆*^ ^*NLS*^ mice\
APhotographs of *Fus* ^+/+^ and *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^ pups immediately after birth (P0 animals).B, C*Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^ mice showed significantly reduced body weight (B) and length (C). Weight and length values normalized to wild type (*Fus* ^+/+^) are presented (mean ± SEM). *N* = 11 *Fus* ^+/+^, *N* = 26 *Fus* ^*Δ*^ ^*NLS*^ ^*/+*^ and *N* = 14 *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^; \**P* \< 0.05, \*\**P* \< 0.01 versus *Fus* ^+/+^, ^\#^ *P* \< 0.05 versus *Fus* ^*∆*^ ^*NLS*^ ^/+^; one‐way ANOVA followed by Tukey\'s *post hoc* test.DRepresentative hematoxylin and eosin stainings of lungs of *Fus* ^+/+^ and *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^ at birth.](EMBJ-35-1077-g004){#embj201592559-fig-0002}

Cytoplasmic FUS mislocalization could have detrimental effects either through toxicity resulting from increased cytoplasmic FUS levels or through loss of its normal nuclear function. To distinguish between these possibilities, we investigated whether complete loss of FUS recapitulates the perinatal lethality phenotype of *Fus* ^*ΔNLS/ΔNLS*^ mice. Mice with a gene trap insertion in exons 8 or 12 of the *Fus* gene have been described previously (Hicks *et al*, [2000](#embj201592559-bib-0029){ref-type="ref"}; Kuroda *et al*, [2000](#embj201592559-bib-0046){ref-type="ref"}), yet both of these *Fus* gene trap lines express low amounts of truncated FUS protein, thus precluding their use to discriminate between loss‐ versus gain‐of‐function mechanisms. To tackle this issue, we generated a novel *Fus* knockout model (hereafter referred to as *Fus* ^*−*/*−*^) that was systematically compared to *Fus* ^*ΔNLS/ΔNLS*^ mice in the same C57Bl6 background. In this new *Fus* knockout allele, a trap cassette was inserted in intron 1 to completely disrupt transcription of the endogenous *Fus* gene (Fig [3](#embj201592559-fig-0003){ref-type="fig"}A). Southern blot and direct sequencing confirmed the position and orientation of the gene trap insertion, and excluded additional insertion events elsewhere in the genome (not shown). FUS protein was undetectable in the central nervous system of *Fus* ^*−*/*−*^ newborn mice by Western blot using the above‐described antibodies against the N‐terminal and C‐terminal parts of the protein (Fig [3](#embj201592559-fig-0003){ref-type="fig"}B and C) and *Fus* mRNA could not be detected by quantitative real‐time PCR (Fig [3](#embj201592559-fig-0003){ref-type="fig"}D). Consistently, immunostaining for FUS on spinal cord sections of E18.5 *Fus* ^*−*/*−*^ mice did not detect FUS protein (Fig [3](#embj201592559-fig-0003){ref-type="fig"}E), confirming that *Fus* ^*−*/*−*^ mice are FUS protein null. Depending on the genetic background, previously described *Fus* gene trap mice were reported either to be adult viable, to die before the age of weaning or within 16 h after birth (Hicks *et al*, [2000](#embj201592559-bib-0029){ref-type="ref"}; Kuroda *et al*, [2000](#embj201592559-bib-0046){ref-type="ref"}; Kino *et al*, [2015](#embj201592559-bib-0044){ref-type="ref"}). In contrast, *Fus* ^*−*/*−*^ mice died within 30 min after birth due to respiratory insufficiency. Similar to *Fus* ^*ΔNLS/ΔNLS*^ pups, the body weight and body length of *Fus* ^*−*/*−*^ newborn mice were significantly reduced as compared to littermate controls (Fig [3](#embj201592559-fig-0003){ref-type="fig"}F and G). Thus, both complete loss of FUS and its cytoplasmic mislocalization trigger a similar perinatal phenotype in C57Bl6 mice.

![Generation of a complete *Fus* ^*−*/*−*^ loss‐of‐function mouse model\
ASchematic representation of the *Fus* gene locus (upper panel). Lower panels depict exons 1--3 in the wild‐type allele (left) and loss‐of‐function allele (right). Arrow: translational start site; SA: splice acceptor; βgeo: β‐galactosidase/neomycin phosphotransferase fusion gene; pA: polyA.BRepresentative immunoblot for FUS on protein extracts of E18.5 brain. Histone 3 is used as a loading control.CQuantification of FUS protein levels from immunoblots.DQuantitative real‐time PCR for *Fus* transcript in *Fus* ^+/+^ *and Fus* ^−/−^ mice. ND: not detected.EImmunostaining for the neuronal marker NeuN and FUS on the spinal cord ventral horn of E18.5 *Fus* ^+/+^ and *Fus* ^*−*/*−*^ mice.F, GBody weight (F) and length (G) of *Fus* ^+/+^, *Fus* ^+/−^, and *Fus* ^−/−^ pups at birth; *N* = 14 *Fus* ^+/+^, *N* = 36 *Fus* ^+/−^, and *N* = 13 *Fus* ^*−*/*−*^ for body weight; *N* = 6 per genotype for body length.Data information: Data represent mean ± SEM. \*\**P* \< 0.01 versus *Fus* ^+/+^, ^\#\#^ *P* \< 0.01 versus *Fus* ^+/*−*^; one‐way ANOVA followed by Tukey\'s *post hoc* test.Source data are available online for this figure.](EMBJ-35-1077-g006){#embj201592559-fig-0003}

Extensive overlap of RNA expression changes induced by cytoplasmic FUS mislocalization and complete loss of FUS {#embj201592559-sec-0005}
---------------------------------------------------------------------------------------------------------------

The phenotypic similarity of *Fus* ^*ΔNLS/ΔNLS*^ and *Fus* ^*−*/*−*^ newborn mice is consistent with FUS cytoplasmic mislocalization leading to loss of FUS nuclear function. FUS has been involved in the regulation of gene expression and alternative splicing of its mRNA targets (Polymenidou *et al*, [2011](#embj201592559-bib-0067){ref-type="ref"}; Tollervey *et al*, [2011](#embj201592559-bib-0085){ref-type="ref"}; Ishigaki *et al*, [2012](#embj201592559-bib-0037){ref-type="ref"}; Lagier‐Tourenne *et al*, [2012](#embj201592559-bib-0048){ref-type="ref"}; Rogelj *et al*, [2012](#embj201592559-bib-0069){ref-type="ref"}). In addition, FUS interacts with several proteins, including U1‐snRNP (Yamazaki *et al*, [2012](#embj201592559-bib-0096){ref-type="ref"}; Sun *et al*, [2015](#embj201592559-bib-0082){ref-type="ref"}), SMN (Yamazaki *et al*, [2012](#embj201592559-bib-0096){ref-type="ref"}; Groen *et al*, [2013](#embj201592559-bib-0027){ref-type="ref"}; Tsuiji *et al*, [2013](#embj201592559-bib-0087){ref-type="ref"}; Sun *et al*, [2015](#embj201592559-bib-0082){ref-type="ref"}), HDAC1 (Wang *et al*, [2013](#embj201592559-bib-0094){ref-type="ref"}), Drosha (Morlando *et al*, [2012](#embj201592559-bib-0060){ref-type="ref"}), RNA polymerase II (Schwartz *et al*, [2012](#embj201592559-bib-0074){ref-type="ref"}), and PRMT1 (Tibshirani *et al*, [2014](#embj201592559-bib-0084){ref-type="ref"}), known to have profound effects on splicing and gene expression. Hence, the expression of a truncated cytoplasmic form of FUS may primarily lead to loss of nuclear FUS function and defective regulation of direct FUS RNA targets. In addition, cytoplasmic accumulation of FUS may also alter the function and/or subcellular localization of FUS‐interacting proteins and result in additional gene expression and splicing alterations. To discriminate between gain‐ and loss‐of‐function changes, we systematically compared RNA profiles in brains from *Fus* ^*ΔNLS/ΔNLS*^ and *Fus* ^*−*/*−*^ mice. First, we used strand‐specific, genomewide sequencing of RNAs (Parkhomchuk *et al*, [2009](#embj201592559-bib-0065){ref-type="ref"}) (RNA‐seq) to evaluate RNA expression levels in brains of *Fus* ^*ΔNLS/ΔNLS*^ and *Fus* ^*−*/*−*^ mice. Total RNA was extracted from E18.5 embryonic brains of *Fus* ^*ΔNLS/ΔNLS*^ mice (*N* = 5), and wild‐type littermates (*N* = 4), as well as homozygous *Fus* ^*−*/*−*^ (*N* = 5) and their control *Fus* ^*+/+*^ littermates (*N* = 5). Expression levels for each annotated protein‐coding gene were determined by the number of mapped fragments per kilobase of exon, per million mapped reads (FPKM) (Mortazavi *et al*, [2008](#embj201592559-bib-0061){ref-type="ref"}; Trapnell *et al*, [2012](#embj201592559-bib-0086){ref-type="ref"}). The FPKM ratio of the *Fus* gene confirmed that *Fus* was expressed in *Fus* ^*ΔNLS/ΔNLS*^ mice, but not in *Fus* ^*−*/*−*^ mice (Fig [EV3](#embj201592559-fig-0003ev){ref-type="fig"}A). Inspection of the reads mapped on the *Fus* gene demonstrated the absence of reads throughout all exons for the *Fus* ^*−*/*−*^ mice, while only exon 15 was not integrated in *Fus* transcripts of *Fus* ^*ΔNLS/ΔNLS*^ mice (Fig [4](#embj201592559-fig-0004){ref-type="fig"}A). *Fus* transcript levels as determined by FPKM ratio were not significantly different in *Fus* ^*ΔNLS/ΔNLS*^ and *Fus* ^*+/+*^ mice (Fig [EV3](#embj201592559-fig-0003ev){ref-type="fig"}A). Unsupervised hierarchical clustering with all genes reliably discriminated mutant genotypes from their controls (Fig [EV3](#embj201592559-fig-0003ev){ref-type="fig"}B and C), indicating that both *Fus* mutation and *Fus* deletion displayed RNA expression profiles divergent from wild type. Statistical comparison of FPKM values identified 237 genes upregulated and 549 genes downregulated in *Fus* ^*ΔNLS/ΔNLS*^ mice ([Dataset EV1](#embj201592559-sup-0005){ref-type="supplementary-material"} and Fig [4](#embj201592559-fig-0004){ref-type="fig"}B). Of note, only nine genes and 56 genes were upregulated and downregulated more than 1.5‐fold, respectively ([Dataset EV1](#embj201592559-sup-0005){ref-type="supplementary-material"}). Identical analysis in *Fus* ^*−*/*−*^ mice identified 669 upregulated genes (29 genes more than 1.5‐fold) and 889 downregulated genes (72 genes more than 1.5‐fold) ([Dataset EV2](#embj201592559-sup-0006){ref-type="supplementary-material"} and Fig [4](#embj201592559-fig-0004){ref-type="fig"}C). Comparison of both models identified 353 genes that were altered in the same direction, consistent with loss of FUS nuclear function underlying the altered levels of these transcripts (Fig [4](#embj201592559-fig-0004){ref-type="fig"}D and [Dataset EV3](#embj201592559-sup-0007){ref-type="supplementary-material"}).

![Genomewide expression changes identified by RNA‐seq in *Fus^ΔNLS/ΔNLS^* and *Fus* ^*−*/*−*^ brains\
Quantification of *Fus* RNA levels by strand‐specific RNA sequencing in brains from *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^ (blue bars), *Fus* ^*−*/*−*^ (red bars), and control littermates (*Fus* ^+/+^, black bars). RNA levels were determined by fragments per kilobase of transcript per million mapped reads (FPKM) value.Unsupervised hierarchical cluster analysis using all RNAs expressed in brains of *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^ mice (KI‐1 to KI‐5) and their control littermates (Ctrl‐1 to Ctrl‐4).Unsupervised hierarchical cluster analysis using all RNAs expressed in brains of *Fus* ^*−*/*−*^ mice (KO‐1 to KO‐5) and their control littermates (Ctrl‐1 to Ctrl‐5).](EMBJ-35-1077-g007){#embj201592559-fig-0003ev}

![FUS‐dependent expression changes in mouse brain\
RNA‐seq reads from brain of homozygous knockin (*Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^, upper panel), homozygous knockout (*Fus* ^*−*/*−*^, middle panel), and control (*Fus* ^+/+^, lower panel) mice showing the absence of exon 15 (red arrow) in *Fus* mRNA in *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^ mice, while the entire *Fus* transcript is absent in *Fus* ^*−*/*−*^ mice (green arrows).Heat map with hierarchical clustering of RNA‐seq data from biological replicates of *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^ (*N* = 5) and control littermates (*N* = 4), showing genes differentially regulated between both genotypes among which 237 are upregulated and 549 are downregulated in *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^ animals as defined by *P *\<* *0.05 adjusted for multiple testing.Heat map with hierarchical clustering of RNA‐seq data from biological replicates of *Fus* ^*−*/*−*^ (*N* = 5) and control littermates (*N* = 5), showing genes differentially regulated between both genotypes, among which 669 are upregulated and 889 are downregulated in *Fus* ^*−*/*−*^ animals as defined by *P *\<* *0.05 adjusted for multiple testing.Venn diagram showing the number of overlapping genes misregulated in *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^ (blue circle) and *Fus* ^*−*/*−*^ (red circle) brains with 353 genes similarly downregulated or upregulated upon cytoplasmic mislocalization or complete loss of FUS.Normalized expression (based on FPKM from RNA‐seq) of genes identified by RNA‐seq to be significantly downregulated (*Ahi1, Kcnip1, Nefm, Nefl, Tuba4a, Dmpk, Rad9b, Stac3, Hist1h2bc, Hist1h1c*) or upregulated (*Fam193b, Pmm2, Bphl, Taf15*) in both *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^ and *Fus* ^*−*/*−*^ compared to their control. Error bars represent SEM in 4‐5 biological replicates. \*\**P* \< 0.01, two‐tailed student\'s *t*‐test.Normalized expression (based on FPKM from RNA‐seq) of genes identified by RNA‐seq to be uniquely changed in *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^ mice (*Trove2, Uhmk1, Ssh3, Vtn, Snrpb, Ephb3*). Error bars represent SEM in 4--5 biological replicates. \**P* \< 0.05, \*\**P* \< 0.01, two‐tailed Student\'s *t*‐test.](EMBJ-35-1077-g008){#embj201592559-fig-0004}

Downregulation of selected genes in both mouse models was confirmed by qRT--PCR ([Appendix Fig S1A](#embj201592559-sup-0001){ref-type="supplementary-material"}) yielding data similar to the RNA‐seq results (Fig [4](#embj201592559-fig-0004){ref-type="fig"}E). Out of these, several genes have been previously involved in neurological diseases such as the *Abelson helper integration site 1* (*Ahi1*) gene mutated in the neurodevelopmental Joubert syndrome (Ferland *et al*, [2004](#embj201592559-bib-0022){ref-type="ref"}), the *Dystrophia myotonica protein kinase* (*Dmpk*) gene implicated in myotonic dystrophy type 1, the *low* and *medium* molecular weight *neurofilamen*t subunits (*Nefl* and *Nefm*) (Bergeron *et al*, [1994](#embj201592559-bib-0006){ref-type="ref"}), and the gene encoding tubulin alpha 4A (*Tuba4a*) that was recently implicated in ALS (Smith *et al*, [2014](#embj201592559-bib-0078){ref-type="ref"}). Similarly, selected upregulated genes were confirmed by qRT--PCR (Fig [4](#embj201592559-fig-0004){ref-type="fig"}E and [Appendix Fig S1A](#embj201592559-sup-0001){ref-type="supplementary-material"}), including *Taf15,* a FUS family member also mutant in ALS (Couthouis *et al*, [2011](#embj201592559-bib-0013){ref-type="ref"}). Increased levels of *Taf15* in *Fus* ^*ΔNLS/ΔNLS*^ and *Fus* ^*−*/*−*^ mice are consistent with the presence of FUS binding sites on the *Taf15* transcript (Lagier‐Tourenne *et al*, [2012](#embj201592559-bib-0048){ref-type="ref"}) and may illustrate a mechanism of compensation induced by loss of FUS nuclear function. Overall, an extensive overlap in RNA expression changes was found in *Fus* ^*ΔNLS/ΔNLS*^ and *Fus* ^*−*/*−*^ brains consistent with loss of FUS nuclear function in knockin mice.

Cytoplasmic mislocalization of FUS leads to unique RNA expression changes {#embj201592559-sec-0006}
-------------------------------------------------------------------------

A subset of transcripts were altered uniquely in *Fus* ^*ΔNLS/ΔNLS*^ animals (Fig [4](#embj201592559-fig-0004){ref-type="fig"}F and [Appendix Fig S1B](#embj201592559-sup-0001){ref-type="supplementary-material"}), including the *Vitronectin* (*Vtn*) gene, the *small nuclear ribonucleoprotein polypeptides B and B1* (*Snrpb*) gene*,* the *Trove2* gene encoding for the 60 kDa SS‐A/Ro ribonucleoprotein, and the *U2AF homology motif kinase 1* (*Uhmk1*) gene encoding for the kinase interacting with stathmin (KIS) protein that was implicated in schizophrenia and the regulation of splicing (Manceau *et al*, [2008](#embj201592559-bib-0056){ref-type="ref"}) and local translation in neuritic projections (Cambray *et al*, [2009](#embj201592559-bib-0010){ref-type="ref"}; Pedraza *et al*, [2014](#embj201592559-bib-0066){ref-type="ref"}). Interestingly, *Fus* ^*ΔNLS/ΔNLS*^ animals displayed increased mRNA levels of *Ephb3*, a member of Eph/ephrin signaling pathways crucial in synaptogenesis and previously involved in Alzheimer\'s disease (Sheffler‐Collins & Dalva, [2012](#embj201592559-bib-0076){ref-type="ref"}), while *EphA4,* another member of Eph/ephrin system, has been recently involved in ALS (Van Hoecke *et al*, [2012](#embj201592559-bib-0089){ref-type="ref"}) (Fig [4](#embj201592559-fig-0004){ref-type="fig"}F and [Appendix Fig S1B](#embj201592559-sup-0001){ref-type="supplementary-material"}). Thus, *Fus* ^*ΔNLS/ΔNLS*^ expression profiles largely recapitulated expression profiles of *Fus* ^*−*/*−*^ brains, yet a subset of genes was found specifically associated with the expression of cytoplasmic truncated FUS in *Fus* ^*ΔNLS/ΔNLS*^ brains.

Gene ontology analysis showed that transcripts whose expression was upregulated in *Fus* ^*ΔNLS/ΔNLS*^ animals were enriched for genes involved in mRNA translation and extracellular matrix constituents ([Dataset EV4](#embj201592559-sup-0008){ref-type="supplementary-material"}). In contrast, transcripts upregulated in *Fus* ^*−*/*−*^ brains revealed enrichment for nuclear and nucleolar proteins involved in the regulation of transcription, DNA replication, or regulation of RNA metabolic processes ([Dataset EV5](#embj201592559-sup-0009){ref-type="supplementary-material"}). Gene ontology analysis revealed a similar enrichment for synaptic activity and function among transcripts downregulated in *Fus* ^*ΔNLS/ΔNLS*^ and *Fus* ^*−*/*−*^ animals (Datasets [EV4](#embj201592559-sup-0008){ref-type="supplementary-material"} and [EV5](#embj201592559-sup-0009){ref-type="supplementary-material"}), supporting that cytoplasmic mislocalization of FUS alters the expression of genes involved in synaptogenesis, as a direct consequence of FUS loss of function. Contrastingly, gain of function elicited by cytoplasmic FUS might be more related to alterations in genes related to mRNA translation and extracellular matrix.

Widespread splicing alterations induced by cytoplasmic mislocalization and loss of FUS {#embj201592559-sec-0007}
--------------------------------------------------------------------------------------

To further compare the molecular changes elicited by cytoplasmic FUS mislocalization and FUS loss of function, we asked whether regulation of mRNA splicing was similarly affected in E18.5 brains of *Fus* ^*ΔNLS/ΔNLS*^ mice and *Fus* ^*−*/*−*^ mice. To characterize mRNA splicing, we exploited the [R]{.ul}NA‐mediated oligonucleotide [a]{.ul}nnealing, [s]{.ul}election, and [l]{.ul}igation with next‐generation [seq]{.ul}uencing (RASL‐seq) method (Li *et al*, [2012](#embj201592559-bib-0049){ref-type="ref"}; Zhou *et al*, [2012](#embj201592559-bib-0098){ref-type="ref"}). This approach allowed us to quantitatively profile 3,859 unique alternative splicing events that correspond to exon inclusion or skipping events conserved between mouse and human (Fig [EV4](#embj201592559-fig-0004ev){ref-type="fig"}). Ratios of shorter to longer mRNA isoform counts were calculated and used to statistically compare the splicing changes between different groups. Unsupervised hierarchical clustering for all splicing events showed that mutant and deleted *Fus* mice clustered apart from their controls (Fig [EV4](#embj201592559-fig-0004ev){ref-type="fig"}B and C). In *Fus* ^*ΔNLS/ΔNLS*^ brains, 9.3% (173 events) of the 1,852 detected splicing events were different from controls, with 101 increased long splicing isoforms and 72 enhanced short isoforms (defined by *t*‐test with *P* \< 0.05 and average fold change \> 1.5) (Fig [5](#embj201592559-fig-0005){ref-type="fig"}A and [Dataset EV6](#embj201592559-sup-0010){ref-type="supplementary-material"}). Heterozygous *Fus* ^*ΔNLS/+*^ mice clustered with wild‐type mice demonstrating that their splicing profile is not significantly altered ([Appendix Fig S2](#embj201592559-sup-0001){ref-type="supplementary-material"}). Nevertheless, heat map of the 173 events significantly changed in homozygous *Fus* ^*ΔNLS/ΔNLS*^ mice showed an intermediate pattern in *Fus* ^*ΔNLS/+*^ heterozygous littermates supporting a partial loss of FUS function in these mice ([Appendix Fig S2](#embj201592559-sup-0001){ref-type="supplementary-material"}). In *Fus* ^*−*/*−*^ brains, 17.9% (252 events) of the 1,406 detected splicing events were different from control littermates, with 118 increased long isoforms and 134 enhanced short isoforms (Fig [5](#embj201592559-fig-0005){ref-type="fig"}B and [Dataset EV7](#embj201592559-sup-0011){ref-type="supplementary-material"}).

![FUS‐dependent splicing alterations identified by RASL‐seq\
Schematic representation of the RASL‐seq strategy to measure ratios of alternative splicing isoforms from thousands of selected splicing events by high‐throughput sequencing.Unsupervised hierarchical cluster analysis using all splicing events sequenced in brains of *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^ mice (KI‐1 to KI‐4), *Fus* ^*Δ*^ ^*NLS*^ ^*/+*^ (HET‐1 to HET‐4), and their control littermates (Ctrl‐1 to Ctrl‐4).Unsupervised hierarchical cluster analysis using all splicing events sequenced in brains of *Fus* ^*−*/*−*^ mice (KO‐1 to KO‐5) and their control littermates (Ctrl‐1 to Ctrl‐5).Venn diagram showing the number of overlapping splicing events that are misregulated in *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^ (blue circle) and *Fus* ^*−*/*−*^ (red circle) brains with 75 exons similarly altered upon cytoplasmic mislocalization or complete loss of FUS.Heat map using the fold changes of the 75 splicing events commonly regulated in *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^ and *Fus* ^*−*/*−*^ mice showing that 100% of the events were differentially included or excluded in the same direction.Semi‐quantitative RT--PCR analyses of selected targets shown in Fig [5](#embj201592559-fig-0005){ref-type="fig"}C with alternatively spliced exons depicted in orange boxes with their flanking constitutive exons in blue boxes.](EMBJ-35-1077-g009){#embj201592559-fig-0004ev}

![FUS‐dependent alternative splicing alterations in mouse brain\
Heat map with hierarchical clustering of RASL‐seq data from biological replicates of *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^ (*N* = 4) and control littermates (*N* = 4), showing 173 alternative splicing alterations associated with expression of cytoplasmic FUS in knockin animals.Heat map with hierarchical clustering of RASL‐seq data from biological replicates of *Fus* ^*−*/*−*^ (*N* = 5) and control littermates (*N* = 5), showing 252 alternative splicing alterations associated with loss of FUS in knockout animals.Semi‐quantitative RT--PCR analyses of selected targets. Left panels show representative acrylamide gel pictures of RT--PCR products. Quantification of splicing changes from at least three biological replicates of *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^ (blue bars) and *Fus* ^*−*/*−*^ (red bars) compared to their control littermates (*Fus* ^+/+^, black bars) by semi‐quantitative RT--PCR (middle panel) and RASL‐seq (right panel) are shown. Error bars represent SEM. \**P* \< 0.05, \*\**P* \< 0.01, two‐tailed Student\'s *t*‐test.](EMBJ-35-1077-g010){#embj201592559-fig-0005}

Comparison of the splicing changes between *Fus* ^*ΔNLS/ΔNLS*^ and *Fus* ^*−*/*−*^ mice revealed a striking overlap between both models. Seventy‐five splicing events were commonly regulated in *Fus* ^*ΔNLS/ΔNLS*^ and *Fus* ^*−*/*−*^ mice, 100% of which were differentially included or excluded in the same direction (Fig [EV4](#embj201592559-fig-0004ev){ref-type="fig"}D and E and [Dataset EV8](#embj201592559-sup-0012){ref-type="supplementary-material"}).

Semi‐quantitative RT--PCR of selected RNAs confirmed these FUS‐dependent splicing changes (Figs [5](#embj201592559-fig-0005){ref-type="fig"}C and [EV4](#embj201592559-fig-0004ev){ref-type="fig"}F), including transcripts previously implicated in neurodegenerative diseases such as the N‐myc downstream‐regulated gene 2 (*Ndrg2*) that is misaccumulated in Alzheimer\'s disease (Mitchelmore *et al*, [2004](#embj201592559-bib-0059){ref-type="ref"}), the microtubule‐associated protein tau (*Mapt*) gene mutated in frontotemporal dementia (Hutton *et al*, [1998](#embj201592559-bib-0034){ref-type="ref"}), the ataxin 2 (*Atxn2*) gene mutated in ALS (Elden *et al*, [2010](#embj201592559-bib-0020){ref-type="ref"}), spinocerebellar ataxia type 2 (SCA2) (Imbert *et al*, [1996](#embj201592559-bib-0036){ref-type="ref"}), and the pro‐neurotrophin receptor sortilin 1 (*Sort1*) (Hu *et al*, [2010](#embj201592559-bib-0031){ref-type="ref"}). Interestingly, inclusion of sortilin 1 exon 17b \[also referred to as exon 18 in Polymenidou *et al* ([2011](#embj201592559-bib-0067){ref-type="ref"})\] was previously associated with low levels of TDP‐43 (Polymenidou *et al*, [2011](#embj201592559-bib-0067){ref-type="ref"}; Prudencio *et al*, [2012](#embj201592559-bib-0068){ref-type="ref"}) and found significantly increased in cortex of FTD patients with TDP‐43 proteinopathy (Prudencio *et al*, [2012](#embj201592559-bib-0068){ref-type="ref"}). Here, we observe that *Fus* mutation and deletion have an opposite effect on sortilin 1 as compared to TDP‐43, with decreased inclusion of exon 17b in embryonic brains from both *Fus* ^*ΔNLS/ΔNLS*^ and *Fus* ^*−*/*−*^ mice (Figs [5](#embj201592559-fig-0005){ref-type="fig"}C and [EV4](#embj201592559-fig-0004ev){ref-type="fig"}F).

Despite expected developmental differences in the alternative splicing patterns of embryonic and adult brains, 57 splicing events found misregulated by RASL‐seq in *Fus* ^*ΔNLS/ΔNLS*^ and *Fus* ^*−*/*−*^ mice were also identified by Affymetrix microarrays in striatum from adult wild‐type mice with antisense oligonucleotide‐mediated depletion of *Fus* (Lagier‐Tourenne *et al*, [2012](#embj201592559-bib-0048){ref-type="ref"}), or in embryonic brains from another *Fus* knockout model that expresses low levels of truncated FUS protein (Hicks *et al*, [2000](#embj201592559-bib-0029){ref-type="ref"}; Lagier‐Tourenne *et al*, [2012](#embj201592559-bib-0048){ref-type="ref"}). Among FUS‐dependent alterations, abnormal splicing of *Mapt* exon 10 (Figs [5](#embj201592559-fig-0005){ref-type="fig"}C and [EV4](#embj201592559-fig-0004ev){ref-type="fig"}F) is of particular relevance for disease pathogenesis as mutations enhancing exon 10 inclusion are linked to frontotemporal dementia (Liu & Gong, [2008](#embj201592559-bib-0053){ref-type="ref"}). While in embryonic mouse brains the predominant mRNA isoforms of *Mapt* do not include exon 10 and encode for tau protein with three microtubule binding repeats (3R‐tau) (McMillan *et al*, [2008](#embj201592559-bib-0057){ref-type="ref"}; Dillman *et al*, [2013](#embj201592559-bib-0017){ref-type="ref"}), we observed increased inclusion of exon 10 encoding for the 4‐repeat tau isoform (4R tau) in both *Fus* ^*ΔNLS/ΔNLS*^ and *Fus* ^*−*/*−*^ mice. In all, splicing alterations caused by cytoplasmic FUS mislocalization are largely overlapping with those elicited by complete loss of FUS. Nevertheless, a subset of events were uniquely found in *Fus* ^*ΔNLS/ΔNLS*^ (Fig [EV4](#embj201592559-fig-0004ev){ref-type="fig"}D), which may be the consequence of functional disruption of other RNA‐binding proteins by abnormal accumulation of FUS in the cytoplasm.

Cytoplasmic mislocalization of FUS leads to increased perinatal motor neuron apoptosis {#embj201592559-sec-0008}
--------------------------------------------------------------------------------------

We next asked whether perinatal death of *Fus* ^*ΔNLS/ΔNLS*^ and *Fus* ^*−*/*−*^ mice was accompanied by loss of motor neurons in the lumbar spinal cord. Immunostaining for choline acetyltransferase (ChAT), which specifically labels large motor neurons in the spinal cord ventral horn, revealed that the number of motor neurons was reduced by approximately 30% in *Fus* ^*ΔNLS/ΔNLS*^ mice as compared with both *Fus* ^*+/+*^ and *Fus* ^*ΔNLS/+*^ mice (Fig [6](#embj201592559-fig-0006){ref-type="fig"}A and B). To exclude the possibility that this reduced number of ChAT‐positive motor neurons reflected downregulation of ChAT expression rather than loss of motor neurons, we also performed Nissl staining, a histochemical stain that does not rely on the expression level of a specific marker. Quantification of neurons with an area of ≥ 80 μm^2^ revealed a 50% reduction in the number of large motor neurons in the ventral horn of *Fus* ^*ΔNLS/ΔNLS*^ newborn mice (Fig [6](#embj201592559-fig-0006){ref-type="fig"}C). Interestingly, *Fus* ^*ΔNLS/+*^ mice displayed a smaller but statistically significant loss of large Nissl‐stained cells, suggesting that motor neurons were also affected in these mice despite showing normal numbers of ChAT‐positive cells. In striking contrast with the situation in *Fus* ^*ΔNLS/ΔNLS*^ mice, spinal motor neuron counts were similar between *Fus* ^*−*/*−*^ mice and their wild‐type littermates (Fig [6](#embj201592559-fig-0006){ref-type="fig"}A, D and E), demonstrating that the mutant FUS protein expressed in *Fus* ^*ΔNLS/ΔNLS*^ mice is toxic to motor neurons during development. Besides motor neuron degeneration, neither *Fus* ^*ΔNLS/ΔNLS*^ nor *Fus* ^*−*/*−*^ mice displayed gross developmental abnormalities of the brain. Indeed, cortical thickness appeared normal in both mouse strains ([Appendix Fig S3](#embj201592559-sup-0001){ref-type="supplementary-material"}). In addition, the thickness of layers II‐IV and layers V‐VI defined by CUX1 and CTIP2 immunofluorescence, respectively, was normal in both mouse strains ([Appendix Fig S4](#embj201592559-sup-0001){ref-type="supplementary-material"}).

![Motor neuron loss in *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^ mice\
ARepresentative light microscopy images of spinal cord sections of *Fus* ^+/+^, *Fus* ^*Δ*^ ^*NLS*^ ^/+^, *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^, and *Fus* ^*−*/*−*^ mice at birth stained with cresyl violet (Nissl, A^1^, A^3^ A^5^, A^7^), or anti‐choline acetyltransferase (ChAT, A^2^, A^4^ A^6^, A^8^).B, CQuantification of ChAT ^+^ motor neurons (B) and Nissl^+^ motor neurons (defined as Nissl‐positive cells with a soma area \> 80 µm^2^) (C) per spinal cord ventral horn in *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^ mice (mean ± SEM). For Nissl^+^ *N* = 8 *Fus* ^+/+^, *N* = 5 *Fus* ^*Δ*^ ^*NLS*^ ^/+^, *N* = 7 *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^, and for ChAT ^+^ *N* = 7 per genotype, \*\**P* \< 0.01 versus *Fus* ^+/+^, ^\#\#^ *P* \< 0.01 versus *Fus* ^*∆*^ ^*NLS*^ ^/+^; one‐way ANOVA followed by Tukey\'s *post hoc* test.D, EQuantification of ChAT ^+^ (D) and Nissl^+^ (E) motor neurons per spinal cord ventral horn in *Fus* ^*−*/*−*^ mice (mean ± SEM). *N* = 6 per genotype, no significant differences were found, by Student\'s unpaired *t*‐test.](EMBJ-35-1077-g012){#embj201592559-fig-0006}

At birth, mouse motor neurons are still in the developmental period, and motor neurons that did not efficiently create synaptic contacts with muscles undergo apoptosis until P10 (Kanning *et al*, [2010](#embj201592559-bib-0041){ref-type="ref"}). Supporting an increased perinatal motor neuron apoptosis in *Fus* ^*ΔNLS/ΔNLS*^ mice, the number of apoptotic cells detected by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) was threefold higher in lumbar spinal cord sections of *Fus* ^*ΔNLS/ΔNLS*^ newborn mice than in wild‐type littermates (Fig [7](#embj201592559-fig-0007){ref-type="fig"}A and B). Furthermore, double immunostaining for ChAT and active caspase‐3, labeling motor neurons actively undergoing apoptosis, revealed that motor neuron apoptosis was three times more frequent in *Fus* ^*ΔNLS/ΔNLS*^ than in wild‐type littermates (Fig [7](#embj201592559-fig-0007){ref-type="fig"}C--E). Together, these data indicate that cytoplasmic mislocalization of FUS leads to increased motor neuron death resulting in reduced numbers of lower motor neurons. The absence of motor neuron loss in *Fus* ^*−*/*−*^ mice indicates that cytoplasmic FUS accumulation leads to motor neuron death through a toxic gain‐of‐function mechanism.

![Motor neuron apoptosis in *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^ mice\
ARepresentative images of TUNEL assay in spinal cord of *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^ mice (A^4^‐A^6^) and *Fus* ^+/+^ mice (A^1^‐A^3^).BQuantification of the total number of TUNEL and DRAQ5 (blue) double‐positive cells in *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^ and *Fus* ^+/+^ per spinal cord section. Mean ± SEM,*N* = 3 per genotype, \**P* \< 0.05, by Student\'s unpaired *t*‐test.C, DImmunofluorescence microscopy of spinal cord of *Fus* ^+/+^ (C) and *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^ (D) mice showing active caspase‐3 (green), ChAT (red), and DNA (cyan, DRAQ5).EQuantification of caspase‐3 (Cas3)/ChAT/DRAQ5 triple‐positive cells in *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^ mice. Mean ± SEM,*N* = 7 per genotype, \*\**P* \< 0.01, by Student\'s unpaired *t*‐test.](EMBJ-35-1077-g013){#embj201592559-fig-0007}

Cytoplasmic mislocalization of FUS alters SMN and HDAC1 localization and induces eIF2α phosphorylation {#embj201592559-sec-0009}
------------------------------------------------------------------------------------------------------

We then asked whether cytoplasmic mislocalization of FUS in *Fus* ^*ΔNLS/ΔNLS*^ mice would affect the subcellular localization of some of its interaction partners. Immunostaining for SMN1 revealed that SMN1‐positive nuclear gems were lost in motor neurons of *Fus* ^*ΔNLS/ΔNLS*^ mice (Fig [8](#embj201592559-fig-0008){ref-type="fig"}A), as in cells from ALS patients and mouse models (Yamazaki *et al*, [2012](#embj201592559-bib-0096){ref-type="ref"}; Tsuiji *et al*, [2013](#embj201592559-bib-0087){ref-type="ref"}; Sun *et al*, [2015](#embj201592559-bib-0082){ref-type="ref"}; Yu *et al*, [2015](#embj201592559-bib-0097){ref-type="ref"}) and consistent with enhanced interaction between mutant FUS and SMN1 (Yamazaki *et al*, [2012](#embj201592559-bib-0096){ref-type="ref"}; Gerbino *et al*, [2013](#embj201592559-bib-0025){ref-type="ref"}; Groen *et al*, [2013](#embj201592559-bib-0027){ref-type="ref"}; Sun *et al*, [2015](#embj201592559-bib-0082){ref-type="ref"}; Yu *et al*, [2015](#embj201592559-bib-0097){ref-type="ref"}). Furthermore, HDAC1, another FUS interaction partner (Wang *et al*, [2013](#embj201592559-bib-0094){ref-type="ref"}), showed profoundly abnormal immunoreactivity in *Fus* ^*ΔNLS/ΔNLS*^ mice. Indeed, HDAC1 was diffusely nuclear in cells from wild‐type spinal cords, while in *Fus* ^*ΔNLS/ΔNLS*^ animals HDAC1 immunoreactivity was condensed in 1--3 nuclear foci per cell (Fig [8](#embj201592559-fig-0008){ref-type="fig"}B). Double immunofluorescence in spinal cords from control animals found a weak HDAC1 staining in ChAT‐positive motor neurons contrasting with a strong nuclear signal in neighboring cells. The pattern was strikingly different in *Fus* ^*ΔNLS/ΔNLS*^ animals with HDAC1 aggregation into nuclear foci in ChAT‐positive motor neurons (Fig [8](#embj201592559-fig-0008){ref-type="fig"}C). In contrast to SMN1 and HDAC1, the binding partner of FUS TAF15 remained mostly nuclear in motor neurons from *Fus* ^*ΔNLS/ΔNLS*^ mice ([Appendix Fig S5](#embj201592559-sup-0001){ref-type="supplementary-material"}). Thus, cytoplasmic mislocalization of FUS perturbs the localization, and potentially the function, of specific interaction partners in motor neurons.

![Alterations of SMN,HDAC1, and eIF2α in *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^ mice\
Representative images of SMN (green) immunofluorescence in spinal cord. Nuclear gems, corresponding to SMN‐immunoreactive foci in nuclei, are marked by arrows.HDAC1 immunoreactivity in spinal cord sections of *Fus* ^+/+^ and *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^ mice. Arrows point to HDAC1‐immunoreactive nuclear foci.Representative images of immunofluorescence staining of motor neurons, labeled with ChAT (red) and HDAC1 (green). Examples of HDAC1 immunoreactive foci in motor neurons are indicated by arrows.Representative images of immunofluorescence staining of motor neurons labeled with ChAT (red) and phosphorylated eIF2α (green), a general translational stress response marker. DRAQ5 (cyan) was used to label nuclei.](EMBJ-35-1077-g014){#embj201592559-fig-0008}

In autopsy material of ALS‐FUS patients, FUS‐containing cytoplasmic aggregates are found in neurons and glial cells. These aggregates are usually also immunopositive for ubiquitin (Vance *et al*, [2009](#embj201592559-bib-0090){ref-type="ref"}; Baumer *et al*, [2010](#embj201592559-bib-0005){ref-type="ref"}; Huang *et al*, [2010](#embj201592559-bib-0032){ref-type="ref"}; Kobayashi *et al*, [2010](#embj201592559-bib-0045){ref-type="ref"}; Tateishi *et al*, [2010](#embj201592559-bib-0083){ref-type="ref"}). Despite motor neuron loss in *Fus* ^*ΔNLS/ΔNLS*^ mice, we did not observe FUS‐positive (Fig [1](#embj201592559-fig-0001){ref-type="fig"}E and F) aggregates in motor neurons or cortical neurons of newborn *Fus* ^*ΔNLS/ΔNLS*^ mice. We also did not observe ubiquitin‐positive, poly‐ubiquitin‐positive, or neurofilament‐positive aggregates in the ventral spinal cord of *Fus* ^*ΔNLS/ΔNLS*^ mice (Fig [EV5](#embj201592559-fig-0005ev){ref-type="fig"}A and B). As FUS is recruited to stress granules, and since neuropathology revealed that cytoplasmic protein aggregates in ALS‐FUS patients stain positive for stress granule markers (Baumer *et al*, [2010](#embj201592559-bib-0005){ref-type="ref"}; Dormann *et al*, [2010](#embj201592559-bib-0019){ref-type="ref"}; Liu‐Yesucevitz *et al*, [2010](#embj201592559-bib-0054){ref-type="ref"}), we evaluated the distribution of TIAR, a stress granule marker in the spinal cord ventral horn in *Fus* ^*ΔNLS/ΔNLS*^ mice. TIAR displayed a similar diffuse cytosolic pattern in motor neurons of *Fus* ^*ΔNLS/ΔNLS*^ and control mice (Fig [EV5](#embj201592559-fig-0005ev){ref-type="fig"}C). As an additional marker for cellular stress, we evaluated eIF2α phosphorylation, which occurs in response to cellular stress and results in decreased global protein translation (Holcik & Sonenberg, [2005](#embj201592559-bib-0030){ref-type="ref"}; Sonenberg & Hinnebusch, [2009](#embj201592559-bib-0079){ref-type="ref"}). Immunostaining for the phosphorylated form of eIF2α revealed a diffuse cytoplasmic staining that was substantially more intense in spinal motor neurons of *Fus* ^*ΔNLS/ΔNLS*^ mice as compared to controls (Fig [8](#embj201592559-fig-0008){ref-type="fig"}D) reflecting cellular stress in *Fus* ^*ΔNLS/ΔNLS*^ motor neurons, with consequent repression of protein translation.

![The absence of protein aggregates and stress granules in *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^ mice\
Representative images of ubiquitin staining (green) in the ventral spinal cord.Representative images of immunofluorescence staining of neurofilament heavy chain (green) and poly‐ubiquitin (lysine 48; red). The neurofilament immunostaining shows normal filamentous staining, and the poly‐ubiquitin staining is very weak and shows no positive aggregates.Representative images of immunofluorescence staining of neurons labeled with NeuN (green) and TIAR (red), a stress granule marker.](EMBJ-35-1077-g011){#embj201592559-fig-0005ev}

Taken together, cytoplasmic mislocalization of FUS in motor neurons led to altered subcellular localization of several of its binding partners accompanied by stress‐induced translational repression, but without the induction of protein aggregation or stress granule formation.

Cytoplasmic FUS mislocalization is intrinsically toxic to motor neurons {#embj201592559-sec-0010}
-----------------------------------------------------------------------

We subsequently asked whether FUS mislocalization within motor neurons is necessary to induce motor neuron loss in *Fus* ^*ΔNLS/ΔNLS*^ mice and therefore evaluated whether restricted expression of wild‐type FUS in motor neurons could rescue their survival despite accumulation of the mutant protein in neighboring cells. We exploited the presence of loxP sites flanking the STOP cassette (Fig [1](#embj201592559-fig-0001){ref-type="fig"}A) to selectively revert the ∆NLS allele to wild type in motor neurons. For this purpose, *Fus* ^*ΔNLS/+*^ mice were crossed to mice expressing the CRE recombinase from the *ChAT* locus, which leads to CRE recombinase activity in virtually all cholinergic neurons (Rossi *et al*, [2011](#embj201592559-bib-0070){ref-type="ref"}; Saxena *et al*, [2013](#embj201592559-bib-0072){ref-type="ref"}). We expected that *Fus* ^*ΔNLS/ΔNLS*^/ChAT‐CRE mice would express truncated FUS protein ubiquitously, except for cholinergic neurons. Double immunostaining for FUS and ChAT on spinal cord sections of *Fus* ^*ΔNLS/ΔNLS*^/*ChAT*‐CRE newborn mice revealed that FUS nuclear localization was indeed largely restored in cholinergic neurons in the ventral spinal cord, but not in other neighboring cells, consistent with motor neuron selective CRE expression (Fig [9](#embj201592559-fig-0009){ref-type="fig"}A). The rescue of FUS nuclear localization was either complete or only partial, with in the latter case motor neurons showing mixed cytoplasmic/nuclear FUS localization (Fig [9](#embj201592559-fig-0009){ref-type="fig"}A), consistent with CRE having successfully recombined at least one *Fus* ^*ΔNLS*^ allele to wild type. Neonatal lethality of *Fus* ^*ΔNLS/ΔNLS*^ mice was not rescued by the *ChAT*‐CRE allele, suggesting that expression of mutant FUS in motor neurons is not the main contributor of neonatal lethality in homozygous mice. Last, we evaluated whether restoration of FUS nuclear localization in motor neurons would prevent motor neuron loss in *Fus* ^*ΔNLS/ΔNLS*^ mice. This approach revealed that the presence of a *ChAT‐*CRE allele was indeed sufficient to fully rescue motor neuron loss (Fig [9](#embj201592559-fig-0009){ref-type="fig"}B--D), as well as restore a normal number of caspase‐3‐positive motor neurons (Fig [9](#embj201592559-fig-0009){ref-type="fig"}E). These findings establish that cytoplasmic FUS mislocalization within motor neurons is required to induce their loss in *Fus* ^*ΔNLS/ΔNLS*^ mice.

![Selective restoration of FUS nuclear import in motor neurons rescues motor neuron loss\
ADouble immunolabeling of spinal cord neurons with ChAT (red) and N‐terminal FUS antibody (green). Nuclei were visualized with DRAQ5 (blue). Cellular localization of FUS was analyzed in the ventral spinal cord of *Fus* ^+/+^/*ChAT*‐CRE (A^1^‐A^4^), *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^/*−* (A^5^‐A^8^), and *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^/*ChAT*‐CRE (A^9^‐A^12^). FUS was completely nuclear in ChAT ^+^ neurons of *Fus* ^+/+^/*ChAT*‐CRE, while cytoplasmic in *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^/*−*. In the ventral horn of *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^/*ChAT*‐CRE mice, ChAT ^+^ neurons (motor neurons, e.g., within the dashed square) displayed nuclear FUS immunoreactivity, while ChAT‐negative cells retained cytoplasmic FUS immunoreactivity (arrows).BRepresentative light microscopy images of spinal cord sections of *Fus* ^+/+^/*ChAT*‐CRE (B^1^, B^4^), *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^/*−* (B^2^, B^5^), and *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^/*ChAT*‐CRE (B^3^, B^6^) mice at birth stained with cresyl violet (Nissl, B^1^‐B^3^) or anti‐choline acetyltransferase (ChAT, B^4^‐B^6^).C, DQuantification of Nissl^+^ (C) and ChAT ^+^ (D) motor neurons per spinal cord ventral horn. Mean ± SEM,*N* = 9 *Fus* ^+/+^/*ChAT*‐CRE,*N* = 8 *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^/*−*, and *N* = 4 *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^/*ChAT*‐CRE for Nissl^+^, and *N* = 11 *Fus* ^+/+^/*ChAT*‐CRE,*N* = 7 *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^/*−*, and *N* = 8 *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^/*ChAT*‐CRE for ChAT ^+^; (\*\*) *P* \< 0.01 versus *Fus* ^*+/+*^, ^\#\#^ *P* \< 0.01 versus *Fus* ^*∆*^ ^*NLS*^ ^/+^; (ns) non‐significant; one‐way ANOVA followed by Tukey\'s *post hoc* test.ETotal numbers of caspase‐3 (Cas3)/ChAT/DAPI triple‐positive cells in *Fus* ^+/+^/*ChAT*‐CRE,*Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^/*−,* and *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^/*ChAT*‐CRE mice. *N* = 9 *Fus* ^+/+^/*ChAT*‐CRE,*N* = 7 *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^/*−,* and *N* = 8 *Fus* ^*Δ*^ ^*NLS*^ ^*/Δ*^ ^*NLS*^/*ChAT*‐CRE; \*\**P* \< 0.01 versus *Fus* ^+/+^, ^\#^ *P* \< 0.05 versus *Fus* ^*∆*^ ^*NLS*^ ^*/+*^; (ns) non‐significant; one‐way ANOVA followed by Tukey\'s *post hoc* test.](EMBJ-35-1077-g015){#embj201592559-fig-0009}

Discussion {#embj201592559-sec-0011}
==========

FUS and other related RBPs form cytoplasmic inclusions associated with nuclear clearance in affected cells from ALS and FTD patients. An outstanding question is whether disease is caused by gain of cytoplasmic toxicity or by loss of the nuclear function of the respective RBP. To gain insight into this conundrum, we targeted the FUS locus to generate two novel mouse models. In the first model, the last exon of *Fus* is no longer transcribed, resulting in the production of a truncated FUS protein that lacks the NLS and localizes almost exclusively to the cytoplasm (Fig [1](#embj201592559-fig-0001){ref-type="fig"}). The second model results in complete loss of FUS expression (Fig [3](#embj201592559-fig-0003){ref-type="fig"}). A thorough comparison of these two models allowed us to determine whether a gain of a toxic cytoplasmic function is required for the observed phenotypes.

Interestingly, this approach revealed that *Fus* ^*ΔNLS/ΔNLS*^ and *Fus* ^*−*/*−*^ mice share several features: both mouse models die shortly after birth due to respiratory insufficiency and exhibit reduced body weight and size. Transcriptomic analysis also revealed overlapping alterations in RNA levels and splicing. However, a reduced number of spinal motor neurons associated with increased perinatal motor neuron apoptosis and a subset of expression and splicing changes were uniquely found in *Fus* ^*ΔNLS/ΔNLS*^ mice (Figs [4](#embj201592559-fig-0004){ref-type="fig"}, [5](#embj201592559-fig-0005){ref-type="fig"}, [6](#embj201592559-fig-0006){ref-type="fig"} and [7](#embj201592559-fig-0007){ref-type="fig"}). Thus, FUS mislocalization to the cytoplasm with reduced levels of nuclear FUS is associated with phenotypes linked to loss of FUS function, but also with motor neuron death induced by a gain of toxicity mechanism that is not recapitulated in the knockout mouse model (Fig [6](#embj201592559-fig-0006){ref-type="fig"}). The notion that loss of FUS function may not be sufficient to induce motor neuron degeneration is also supported by two recent reports. First, in an outbred genetic background, homozygous *Fus* gene trap mice reached 2 years of age without manifesting ALS‐like phenotypes or motor neuron loss (Kino *et al*, [2015](#embj201592559-bib-0044){ref-type="ref"}). Second, selective inactivation of the FUS homolog *cabeza* in neurons of adult *Drosophila* did not affect motor performance or life span, indicating that *cabeza* is not required for maintenance of neuronal function in adults (Frickenhaus *et al*, [2015](#embj201592559-bib-0023){ref-type="ref"}). Here, we demonstrate that loss of FUS function is not sufficient and that gain of function by cytoplasmic redistribution of FUS is necessary to elicit motor neuron apoptosis. Notably, RNA‐seq and RASL‐seq experiments showed that the ∆NLS mutation triggered a partial loss of FUS function in splicing and gene expression regulation. Loss of function, although not sufficient, may be necessary in *Fus* ^*ΔNLS/ΔNLS*^ mice to induce motor neuron death. Indeed, a number of genes involved in synaptogenesis and/or in neurodegenerative diseases show altered expression (*Ahi1, Dmpk, Nefl, Nefm, Tuba4a, Taf15*) or splicing (*Ndrg2, Mapt, Atxn2, Sort1*) in *Fus* ^*ΔNLS/ΔNLS*^ and *Fus* ^*−*/*−*^ mice (Figs [4](#embj201592559-fig-0004){ref-type="fig"} and [5](#embj201592559-fig-0005){ref-type="fig"}), and these alterations linked to loss of FUS nuclear function may weaken the motor neuron and sensitize it to the toxic effects of cytoplasmic FUS accumulation.

Importantly, we showed that motor neuron death in *Fus* ^*ΔNLS/ΔNLS*^ mice could be prevented by selectively restoring FUS nuclear import in motor neurons (Fig [9](#embj201592559-fig-0009){ref-type="fig"}), demonstrating that FUS cytoplasmic mislocalization within motor neurons is required to induce motor neuron loss. The observation that cytoplasmic mislocalization of FUS is intrinsically toxic to motor neurons contrasts with the non‐cell‐autonomous contribution to motor neuron degeneration demonstrated for *SOD1* mutations (Boillee *et al*, [2006](#embj201592559-bib-0008){ref-type="ref"}). Indeed, abrogation of mutant SOD1 expression in motor neurons delayed, but did not prevent, motor neuron degeneration, and a contribution of neighboring cells to SOD1 mediated toxicity is well established (Ilieva *et al*, [2009](#embj201592559-bib-0035){ref-type="ref"}). Moreover, our data support a degenerative rather than developmental origin of motor neuron loss in newborn *Fus* ^*ΔNLS/ΔNLS*^ mice. The reduced number of motor neurons could have a developmental origin, either by impaired proliferation of motor neuron progenitors or defects in acquisition of motor neuron fate. However, this scenario is unlikely since motor neuron loss in *Fus* ^*ΔNLS/ΔNLS*^ mice can be prevented by ChAT‐CRE‐induced reversal of the *Fus* ^*ΔNLS*^ locus to wild type (Fig [9](#embj201592559-fig-0009){ref-type="fig"}). Expression of the ChAT gene, which encodes choline acetyl transferase, an enzyme essential for the biosynthesis of acetylcholine, is detectable in postmitotic motor neurons from E11.5 onwards, thus after exit from the cell cycle and acquisition of motor neuron fate at E.9.5 (Chen & Chiu, [1992](#embj201592559-bib-0011){ref-type="ref"}; Alaynick *et al*, [2011](#embj201592559-bib-0002){ref-type="ref"}; Cho *et al*, [2014](#embj201592559-bib-0012){ref-type="ref"}). Therefore, the pathogenic events driving motor neuron loss in *Fus* ^*ΔNLS/ΔNLS*^ mice occur after motor neuron specification. It should be noted that a large proportion of motor neurons showed an incomplete rescue of FUS nuclear localization. This could be either due to the rescue of one single allele or to the persistence of truncated FUS produced before CRE‐mediated recombination. In any case, only a partial rescue of FUS subcellular localization was sufficient to abrogate motor neuron loss.

An attractive hypothesis to explain motor neuron loss in *Fus* ^*ΔNLS/ΔNLS*^ mice is that excessive motor neuron apoptosis happens during the so‐called natural cell death period. During development, motor neurons are generated in excess and approximately 40% of the initially generated motor neurons are progressively removed. This process ensures the generation of the appropriate number of motor neurons and guarantees the elimination of motor neurons that did not establish proper neuromuscular junctions. According to the "neurotrophin hypothesis", developing motor neurons compete for limited amounts of neurotrophic factors produced by the muscle targets. Only motor axons that establish stable and functional neuromuscular junctions receive sufficient survival signals and are maintained (Oppenheim, [1991](#embj201592559-bib-0064){ref-type="ref"}; Kanning *et al*, [2010](#embj201592559-bib-0041){ref-type="ref"}). Importantly, we found that motor neuron loss elicited by cytoplasmic FUS mislocalization is associated with increased apoptosis of spinal motor neurons (Fig [7](#embj201592559-fig-0007){ref-type="fig"}). Several motor neuron intrinsic mechanisms may underlie increased motor neuron apoptosis in *Fus* ^*ΔNLS/ΔNLS*^ mice and future studies are needed to investigate these possible mechanisms. For instance, expression of axon guidance receptors may be deregulated in *Fus* ^*ΔNLS/ΔNLS*^ mice, leading to defects in motor axon targeting and failure to receive neurotrophic support. Alternatively, *Fus* ^*ΔNLS/ΔNLS*^ motor axons may reach their targets, but reduced expression of receptors for muscle‐derived neurotrophic factors may render a fraction of motor neurons insensitive to survival signals.

Previous work suggested various potential toxic mechanisms for cytoplasmic FUS, and our study sheds light on several of these candidate pathways. First, cytoplasmic FUS could generate toxic FUS aggregates in the cytosol, as shown in yeast models of FUSopathies (Ju *et al*, [2011](#embj201592559-bib-0039){ref-type="ref"}; Sun *et al*, [2011](#embj201592559-bib-0081){ref-type="ref"}). Here, we detected neither FUS‐positive nor ubiquitin‐positive aggregates expected to occur in case of strong ubiquitin proteasome system (UPS) impairment. Thus, at least in this model and at this perinatal age, FUS aggregation or robust FUS‐mediated impairment of protein clearance pathways is dispensable for toxicity toward motor neurons. Cytoplasmic FUS could also alter stress granule (SG) dynamics through its localization to SGs upon stress and its regulatory properties toward SG assembly (Li *et al*, [2013](#embj201592559-bib-0050){ref-type="ref"}). In *Fus* ^ΔNLS/ΔNLS^ mice, we did not observe formation of SGs in spinal cord motor neurons using TIAR as a marker, suggesting that major impairment of SG biology is not required for FUS toxicity *in vivo* in this model. However, we observed increased phosphorylation of the translation initiation factor eIF2α, an event known to be caused by cellular stress and to lead to repression of global protein translation (Holcik & Sonenberg, [2005](#embj201592559-bib-0030){ref-type="ref"}; Sonenberg & Hinnebusch, [2009](#embj201592559-bib-0079){ref-type="ref"}). Consistent with this scenario, gene ontology analysis of differentially expressed genes also pointed to alterations in mRNA translation as a potential function uniquely altered in *Fus* ^*ΔNLS/ΔNLS*^ mice.

In addition to increased eIF2α phosphorylation, several FUS binding partners are affected in their subcellular localization upon cytoplasmic FUS mislocalization. Firstly, SMN1‐positive nuclear gems were lost in *Fus* ^*ΔNLS/ΔNLS*^ motor neurons, likely as a consequence of FUS loss of function, as FUS was shown to be required for gem formation in HeLa cells and primary hippocampal neurons (Yamazaki *et al*, [2012](#embj201592559-bib-0096){ref-type="ref"}; Tsuiji *et al*, [2013](#embj201592559-bib-0087){ref-type="ref"}). Intriguingly, nuclear gems were also reduced in fibroblasts from ALS patients with FUS or TDP‐43 mutations, and in motor neurons in postmortem lumbar spinal cord from ALS patients (Yamazaki *et al*, [2012](#embj201592559-bib-0096){ref-type="ref"}; Tsuiji *et al*, [2013](#embj201592559-bib-0087){ref-type="ref"}; Sun *et al*, [2015](#embj201592559-bib-0082){ref-type="ref"}). Furthermore, we observed a dramatic concentration of HDAC1 in nuclear foci in *Fus* ^*ΔNLS/ΔNLS*^ neurons. The exact consequences of this abnormal HDAC1 localization remain to be determined, but the pleiotropic functions of HDAC1 in cell survival, axonal damage, and repair of DNA damage (Kim *et al*, [2010](#embj201592559-bib-0042){ref-type="ref"}; Wang *et al*, [2013](#embj201592559-bib-0094){ref-type="ref"}) suggest that downstream consequences of abnormal HDAC1 distribution might underlie toxicity. In any case, the abnormal subcellular localizations of HDAC1 and SMN in *Fus* ^*ΔNLS/ΔNLS*^ neurons provide evidence that FUS cytoplasmic mislocalization could lead to alterations in splicing or gene expression through cytoplasmic retention or abnormal trafficking of its interaction partners.

An interesting observation is that both *Fus* ^*ΔNLS/ΔNLS*^ and *Fus* ^*−*/*−*^ mice die shortly after birth of respiratory insufficiency, presumably caused by loss of FUS function. A concerted action of several physiological systems is required for newborn mice to breathe normally, and defects in any of these systems can lead to neonatal lethality (Turgeon & Meloche, [2009](#embj201592559-bib-0088){ref-type="ref"}). Firstly, the respiratory rhythm is generated in the respiratory center in the brainstem and transmitted through the spinal motor neurons to the respiratory muscles (diaphragm and intercostals muscles). Therefore, structural or functional defects of neurons in the respiratory center, motor neurons, neuromuscular junctions, and/or respiratory muscles can lead to respiratory distress. Our observation that neonatal lethality of *Fus* ^*ΔNLS/ΔNLS*^ mice is not rescued by restoration of FUS nuclear import in motor neurons indicates that loss of FUS function in cell types other than motor neurons is sufficient to trigger neonatal lethality. Alternatively, the expression of CRE under the *ChAT* promoter may occur too late in the development to provide a complete rescue of the motor neurons functionality. The remaining cytoplasmic FUS observed in rescued motor neurons could result either from a long half‐life of FUS protein in motor neurons or from CRE‐mediated recombination of only one allele. Thus, rescued motor neurons, despite being histologically normal, could remain functionally altered due to residual cytoplasmic FUS. This would be analogous to results observed in Nova double knockout animals rescued with neuronal agrin (Ruggiu *et al*, [2009](#embj201592559-bib-0071){ref-type="ref"}). Electrophysiological characterization of neuromuscular transmission could help discriminate between these two possibilities. Apart from neuromuscular alterations, defects in lung morphogenesis or maturation, cardiovascular defects, hematological defects, or skeletal defects can all result in poor blood oxygenation and the characteristic cyanosis observed in *Fus* ^*ΔNLS/ΔNLS*^ and *Fus* ^*−*/*−*^ neonates. It will be important to investigate these possible causes of neonatal lethality due to loss of FUS function in future studies. In particular, generation of conditional *Fus* knockout mice would provide a valuable tool to evaluate whether selective FUS inactivation in neurons, muscle, lung epithelium, or the vasculature would result in respiratory insufficiency and neonatal death. Possibly, loss of FUS function in a combination of these tissues is necessary to induce this phenotype.

While a few FUS mutations have a recessive pattern of inheritance (Kwiatkowski *et al*, [2009](#embj201592559-bib-0047){ref-type="ref"}; Bertolin *et al*, [2014](#embj201592559-bib-0007){ref-type="ref"}), the vast majority are dominantly inherited, and most ALS patients are affected in their 5^th^ to 7^th^ decade. Thus, our observation of perinatal death is not fully representative of the disease state as occurs in ALS patients and some changes observed here might be deleterious through developmental rather than degenerative effects. In this respect, it will be crucial to further analyze heterozygous *Fus* ^*ΔNLS/+*^ mice that closely mimic the genetic situation in the vast majority of ALS‐FUS patients. These mice are viable and show no obvious motor phenotype until 6 months of age (Scekic‐Zahirovic, unpublished results). Nevertheless, *Fus* ^*ΔNLS/+*^ mice showed cytoplasmic mislocalization of FUS and subtle alterations in mRNA splicing at birth. Aging might exacerbate these defects, consistent with a late‐onset disease such as ALS, and it will be highly interesting to characterize a potential age‐dependent phenotype of *Fus* ^*ΔNLS/+*^ mice and *Fus* ^*+*/*−*^ mice.

The very severe phenotype of *Fus* ^*ΔNLS/ΔNLS*^ mice resembles spinal muscular atrophy, which is caused by mutations in the *SMN1* gene, whose product SMN interacts directly with FUS and is an integral component of the spliceosome (Yamazaki *et al*, [2012](#embj201592559-bib-0096){ref-type="ref"}; Gerbino *et al*, [2013](#embj201592559-bib-0025){ref-type="ref"}; Groen *et al*, [2013](#embj201592559-bib-0027){ref-type="ref"}; Tsuiji *et al*, [2013](#embj201592559-bib-0087){ref-type="ref"}; Sun *et al*, [2015](#embj201592559-bib-0082){ref-type="ref"}; Yu *et al*, [2015](#embj201592559-bib-0097){ref-type="ref"}). This is further reinforced by the strong splicing defects observed in *Fus* ^*ΔNLS/ΔNLS*^ mice and is consistent with juvenile onset in many ALS‐*FUS* patients with C‐terminal truncation mutations. These similarities strengthen the links between ALS and SMA, and support that SMA, ALS, and FTD may be part of the same disease spectrum with common molecular mechanisms leading to neuronal death.

In conclusion, this study provides *in vivo* genetic evidence that cytoplasmic mislocalization of FUS triggers apoptotic motor neuron degeneration and demonstrates a crucial role for a gain of toxic function in this process. Motor neuron loss occurs at least partially through a cell autonomous gain‐of‐function mechanism, since complete loss of FUS is not associated with motor neuron death, and rescue of nuclear FUS within motor neurons prevents neuronal death.

Materials and Methods {#embj201592559-sec-0012}
=====================

Generation of conditional knockin *Fus* ^*ΔNLS/ΔNLS*^ and *Fus* ^*−*/*−*^ mice {#embj201592559-sec-0013}
------------------------------------------------------------------------------

Knockin *Fus* mice with the conditional ablation of exon 15 were generated in the Institut Clinique de la Souris (ICS, Illkirch, Strasbourg) using standard procedures. The *Fus* locus was engineered to include, in between the exons 12 and 13 of the gene, an inserted floxed cDNA encoding exons 13 and 14 of *FUS*, followed by 3 STOP cassettes. We obtained germ line transmission of the recombinant allele. Homozygous *Fus* ^*ΔNLS/ΔNLS*^ mice were generated by intercrossing *Fus* ^*ΔNLS/+*^ animals.

For generation of *Fus* ^*−*/*−*^ mice, the mouse ES cell clone EUCE0131_G08 was obtained from the European Conditional Mouse Mutagenesis Consortium (EUCOMM) (Friedel *et al*, [2007](#embj201592559-bib-0024){ref-type="ref"}). Southern blotting and sequencing of PCR‐amplified genomic sequences confirmed a single gene trap insertion event in the first intron of *Fus*. Blastocyst injection of ES cells resulted in chimeric mice, which allowed for germ line transmission of the mutant *Fus* allele. As the ES cells were generated in a 129P2 background, the resulting offspring was backcrossed at least five times to C57Bl6 mice. The genetic background of all mice used in this study is C57Bl6.

Western blot {#embj201592559-sec-0014}
------------

Western blotting and antibodies used are presented in [Appendix Supplementary Methods](#embj201592559-sup-0001){ref-type="supplementary-material"}.

Histology and motor neuron counts {#embj201592559-sec-0015}
---------------------------------

Spinal cords were removed and immersed in fixative for 2 h at 4°C. Samples were transferred overnight into 30% sucrose in 0.1 M phosphate buffer (PB) at 4°C for cryoprotection, embedded in medium (Tissue‐Tek^®^ O.C.T. Compound, SAKURA\#4583), and cut with a cryostat (Leica CM 3050S). P0 spinal cords were cut in serial 25‐μm‐thick sections and mounted onto 2% gelatin‐coated slides to be processed for immunostaining.

For Nissl staining, slides were air‐dried overnight. Sections were then hydrated through 100% and 95% alcohol to distilled water, immersed in 0.1% Cresyl violet acetate (Certistain^®^, MERCK\#5235), and coverslipped with Roti‐Histokitt (Roth, 6638.1).

For immunohistochemistry (IHC), unspecific binding sites were blocked with 5% horse serum (HS), 0.5% Triton X‐100 for 30 min at room temperature (RT), immersed in 3% hydrogen peroxide (H~2~O~2~) to remove the endogenous peroxidase activity, rinsed in phosphate buffered saline (PBS), and incubated with goat polyclonal anti‐choline acetyltransferase (ChAT) antibody (Millipore, AB144‐P; diluted 1:50) overnight at RT in a humidified chamber. After rinsing in PBS, sections were incubated with biotinylated donkey anti‐goat IgG (Jackson, 705‐066‐147; 1:250) for 1.5 h, rinsed in PBS, and then incubated with ABC kit (Vector, PK7200; 1:4,000) for 1 h. All antibodies were diluted in 0.01 M PBS, 0.1% Triton X‐100. Peroxidase staining was obtained by incubating the sections in 0.075% 3,3′‐diaminobenzidine tetrahydrochloride (DAB; Sigma Aldrich) and 0.002% H~2~O~2~ in 50 mM Tris--HCl pH 7.5. Sections were dehydrated, air‐dried, and coverslipped with Roti‐Histokitt (Roth, 6638.1).

Motor neurons were counted at L1--L5 on both cresyl violet‐ and ChAT‐stained sections at 20× magnification (for each genotype: Exact numbers of animals per group are provided in figure legends). The counting was performed per ventral horn in every tenth section for ten sections in total per animal. In Nissl‐stained sections, only neurons with an area ≥ 80 μm^2^ and located in a position congruent with that of motor neuron groups were counted (d\'Errico *et al*, [2013](#embj201592559-bib-0021){ref-type="ref"}). All ChAT^+^ profiles located in the ventral horns of immunostained sections clearly displayed on the plane of the section were counted. Total estimated motor neuron numbers were obtained using a computer‐assisted microscope (Nikon Eclipse E800) and the software (Nis Elements version 4.0). Cells were counted on the computer screen using a digital camera (Nikon Digital Sight DS‐U3) mounted on a microscope. The soma size of Nissl+ motor neurons was also analyzed by measuring cross‐sectional areas at 20× magnification using ImageJ software (Schneider *et al*, [2012](#embj201592559-bib-0073){ref-type="ref"}).

Other histological techniques are described in [Appendix Supplementary Methods](#embj201592559-sup-0001){ref-type="supplementary-material"}.

Analysis of expression changes by RNA‐seq {#embj201592559-sec-0016}
-----------------------------------------

Total RNA from brains of *Fus* ^*ΔNLS/ΔNLS*^, *Fus* ^*−*/*−*^, and their control littermates were extracted with TRIzol (Invitrogen). RNA quality was measured using the Agilent Bioanalyzer system or RNA ScreenTape (Agilent technologies) according to the manufacturer\'s recommendations and processed using the Illumina TruSeq Stranded mRNA Sample Preparation Kit according to manufacturer\'s protocol. Generated cDNA libraries were sequenced using an Illumina HiSeq 2000 sequencer with 4--5 biological replicates sequenced per condition using single read, 50 cycle runs. Quality of sequencing reads was assessed using FastQC (Babraham Bioinformatics) and then aligned to a mouse reference genome (mm9, UCSC Genome Browser) using TopHat (version v2.0.10). Sequencing yielded, on average, 15 million non‐redundant reads per sample with a 48.4--58.7% mapping rate. Cufflinks (version v2.1.1) was used to generate transcript abundance for each annotated protein‐coding gene as fragments per kilobase of transcript per million mapped reads (FPKM), and statistical analysis and comparison of FPKM values were calculated using Cuffdiff (version v2.1.1). Genomewide unsupervised clustering analysis and heat maps with significant changes between different groups were generated using R (Bioconductor). qRT‐PCR techniques used to confirm RNA‐seq changes are described in [Appendix Supplementary Methods](#embj201592559-sup-0001){ref-type="supplementary-material"} and oligonucleotides sequences are provided in [Dataset EV9](#embj201592559-sup-0013){ref-type="supplementary-material"}.

Analysis of splicing alterations by RASL‐seq {#embj201592559-sec-0017}
--------------------------------------------

RNA‐mediated oligonucleotide [a]{.ul}nnealing, [s]{.ul}election, and [l]{.ul}igation with next‐generation sequencing (RASL‐seq) analysis of alternative splicing changes was carried out as already described elsewhere (Li *et al*, [2012](#embj201592559-bib-0049){ref-type="ref"}; Zhou *et al*, [2012](#embj201592559-bib-0098){ref-type="ref"}). In brief, a pool of oligonucleotides was designed to detect 3,859 alternative splicing events in mice. One hundred fmol of RASL‐seq oligos were annealed to 1 μg of total RNA isolated from brains of *Fus* ^*ΔNLS/ΔNLS*^, *Fus* ^*−*/*−*^, and their control littermates. After ligation, 5 μl eluted ligated oligos were used for 16--18 cycles of PCR amplification, and the barcoded PCR products were sequenced using an Illumina HiSeq 2000 sequencer with 24--30 samples per lanes. Sequencing data were decoded allowing no mismatch with each barcode, and target sequences were mapped with RASL‐seq oligo pool sequences using the short read alignment software Bowtie allowing for 1 mismatch at both the left and right side of the ligated oligos. An average of \~5 million reads from each sample was mapped, with events with \< 4 counts in one of the isoforms removed. Ratios of the counts of shorter to longer isoforms were calculated. The significantly changed events were identified by *t*‐test and average fold change. Unsupervised clustering analysis and heat maps with significant changes between different groups were generated using R (Bioconductor). Semi‐quantitative PCR techniques used to confirm RASL‐seq changes are described in [Appendix Supplementary Methods](#embj201592559-sup-0001){ref-type="supplementary-material"}. Oligonucleotides sequences are provided in [Dataset EV9](#embj201592559-sup-0013){ref-type="supplementary-material"}.

Statistics {#embj201592559-sec-0018}
----------

For the animal experiments, the values from each animal were averaged for each genotype group and analyzed by Student\'s unpaired two‐tailed *t*‐test. Comparison of three or four groups was performed using one‐way ANOVA and Tukey\'s *post hoc* test. Data were analyzed by using the Graphics Prism Program (Graph Pad Software, San Diego, CA) and expressed as mean ± SEM (standard error of the mean) and differences were considered significant when *P* ≤ 0.05.

Data accession {#embj201592559-sec-0019}
--------------

RNA‐seq and RASL‐seq data have been deposited in GEO, under entry GSE78730.
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